McCarthy Daniel Joseph sold $329K of EVH

McCarthy Daniel Joseph (PRESIDENT) sold 65,892 shares of Evolent Health, Inc. (EVH) at $5.00 ($0.33M total) on 2026-08-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · McCarthy Daniel Joseph
Published Aug 28, 2026, 8:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EVH
Neutral
high confidence
Mentioned
$EVH
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EVHNeutralLow
01

Why it matters

Limited impact on EVH stock; the transaction size is modest and pre‑planned.

02

Market read

Routine insider sale with negligible market effect.

03

What to watch

The sale is pre‑arranged under a 10b5‑1 plan, reducing the informational content of the transaction.

Relevance 3/10Novelty 4/10Timing: filed Aug 28 2026

Background

Form 4 filings disclose insider trades; this is a routine sale by the company president.

Company-level read

Ticker impact

$EVHNeutralHigh confidence
Context

President Daniel Joseph McCarthy sold 65,892 shares of EVH for $329,460 via a 10b5‑1 plan.

Expected impact

minimal impact, price likely unchanged

Evidence & confidence

Sale size is small relative to float and disclosed via routine Form 4; no immediate market reaction expected.

Counterpoint

Some traders may view any insider sale as a bearish signal despite the small amount.

Key entities

  • Evolent Health, Inc.

    US‑listed health‑tech firm (ticker EVH).

  • Daniel Joseph McCarthy

    President of EVH, insider selling shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EVHMedAI 8/10

EVH Q3 2026 deep dive: ongoing AI investment and customer expansion shape outlook

EVH reported Q3 2026 revenue of $725.4M (51.3% YoY growth, in line with estimates) and adjusted EPS of $0.06 (in line). Adjusted EBITDA was $34.26M, beating estimates by 3.1%. The company reconfirmed full-year revenue guidance of $2.65B and raised EBITDA guidance to $132.5M. Sales volumes fell 4.2% YoY, while operating margin declined to -0.9%. EVH expanded its AI platform, Oncology care, and National payer scale, citing cost savings and margin expansion potential.

$EVHMed

Evolent Health, Inc. Q3 2026 Earnings Call Summary

Evolent Health reported 11% sequential revenue growth driven by Highmark Performance Suite and contractual adjustments. MER improved to 93%. Management prioritizes margin expansion and cash generation, with oncology expected to represent over 70% of revenue by 2027. AI platform scales, processing 1M cases annually. Management reiterated 2027 Adjusted EBITDA confidence of $150M+ and plans $50M debt reduction by 2026 year-end.

$EVHMedAI 8/10

Evolent Health (EVH) Q3 2026 Earnings Call Transcript

Evolent Health (EVH) reiterated its full-year revenue guidance of $2.6B-$2.7B and raised Adjusted EBITDA guidance to $130M-$135M. The company reported customer contract renewals and expansions, including a 4-year renewal with its largest Surgical Management customer and expansions in oncology and specialty services.

$EVHMed

Evolent Health: Q3 Earnings Snapshot

Evolent Health (EVH) reported a Q3 loss of $23.6M, or 21 cents per share, with adjusted earnings of 6 cents per share, meeting expectations. Revenue was $725.4M, below the $734.3M forecast. The company expects full-year revenue between $2.6B and $2.7B.